Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells

Mayumi Naramura, Stephen D. Gillies, John Mendelsohn, Ralph A. Reisfeld, Barbara M. Mueller

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Functional characteristics were established for a genetically engineered fusion protein between human IL2 and mouse/human chimeric mAb 225 directed against human epidermal growth factor receptor (EGFR), aberrantly expressed on human melanoma cells. The emphasis of these studies was on the mechanism(s) of action by which the ch225-IL2 fusion protein mediated cytotoxic killing of human melanoma cells by different human immune effector cells. Ch225-IL2 fusion protein bound to human EGFR with the high affinity of the parental antibody, and was as active as the equivalent amount of rhIL2. Ch225-IL2 enhanced cellular cytotoxicity mediated by freshly separated PBMC, isolated natural killer (NK) cells and activated T cells against melanoma cell lines. NK cells, which constitutively express both FcγRIII and IL2R, interacted with ch225-IL2, mainly through FcγRIII, while the involvement of IL2R was secondary. However, the effect of ch225-IL2 on activated T cells was most likely mediated through IL2R. These results suggest that the genetically engineered ch225-IL2 fusion protein may become a potent immunotherapeutic agent capable of stimulating various immune effector populations to effectively kill human melanoma cells.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalImmunology Letters
Volume39
Issue number1
DOIs
StatePublished - Dec 1 1993

Fingerprint

Interleukin-2
Melanoma
Antibodies
Proteins
Epidermal Growth Factor Receptor
Natural Killer Cells
T-Lymphocytes
Antibody Affinity
Cell Line
Population

Keywords

  • Cellular cytotoxicity
  • FcγRIII
  • IL2R
  • Immunotherapy
  • Melanoma
  • Recombinant antibody-IL2 fusion protein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. / Naramura, Mayumi; Gillies, Stephen D.; Mendelsohn, John; Reisfeld, Ralph A.; Mueller, Barbara M.

In: Immunology Letters, Vol. 39, No. 1, 01.12.1993, p. 91-99.

Research output: Contribution to journalArticle

Naramura, Mayumi ; Gillies, Stephen D. ; Mendelsohn, John ; Reisfeld, Ralph A. ; Mueller, Barbara M. / Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. In: Immunology Letters. 1993 ; Vol. 39, No. 1. pp. 91-99.
@article{54f68a950e314f67bb9a158f5cf9d4e5,
title = "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells",
abstract = "Functional characteristics were established for a genetically engineered fusion protein between human IL2 and mouse/human chimeric mAb 225 directed against human epidermal growth factor receptor (EGFR), aberrantly expressed on human melanoma cells. The emphasis of these studies was on the mechanism(s) of action by which the ch225-IL2 fusion protein mediated cytotoxic killing of human melanoma cells by different human immune effector cells. Ch225-IL2 fusion protein bound to human EGFR with the high affinity of the parental antibody, and was as active as the equivalent amount of rhIL2. Ch225-IL2 enhanced cellular cytotoxicity mediated by freshly separated PBMC, isolated natural killer (NK) cells and activated T cells against melanoma cell lines. NK cells, which constitutively express both FcγRIII and IL2R, interacted with ch225-IL2, mainly through FcγRIII, while the involvement of IL2R was secondary. However, the effect of ch225-IL2 on activated T cells was most likely mediated through IL2R. These results suggest that the genetically engineered ch225-IL2 fusion protein may become a potent immunotherapeutic agent capable of stimulating various immune effector populations to effectively kill human melanoma cells.",
keywords = "Cellular cytotoxicity, FcγRIII, IL2R, Immunotherapy, Melanoma, Recombinant antibody-IL2 fusion protein",
author = "Mayumi Naramura and Gillies, {Stephen D.} and John Mendelsohn and Reisfeld, {Ralph A.} and Mueller, {Barbara M.}",
year = "1993",
month = "12",
day = "1",
doi = "10.1016/0165-2478(93)90169-3",
language = "English (US)",
volume = "39",
pages = "91--99",
journal = "Immunology Letters",
issn = "0165-2478",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells

AU - Naramura, Mayumi

AU - Gillies, Stephen D.

AU - Mendelsohn, John

AU - Reisfeld, Ralph A.

AU - Mueller, Barbara M.

PY - 1993/12/1

Y1 - 1993/12/1

N2 - Functional characteristics were established for a genetically engineered fusion protein between human IL2 and mouse/human chimeric mAb 225 directed against human epidermal growth factor receptor (EGFR), aberrantly expressed on human melanoma cells. The emphasis of these studies was on the mechanism(s) of action by which the ch225-IL2 fusion protein mediated cytotoxic killing of human melanoma cells by different human immune effector cells. Ch225-IL2 fusion protein bound to human EGFR with the high affinity of the parental antibody, and was as active as the equivalent amount of rhIL2. Ch225-IL2 enhanced cellular cytotoxicity mediated by freshly separated PBMC, isolated natural killer (NK) cells and activated T cells against melanoma cell lines. NK cells, which constitutively express both FcγRIII and IL2R, interacted with ch225-IL2, mainly through FcγRIII, while the involvement of IL2R was secondary. However, the effect of ch225-IL2 on activated T cells was most likely mediated through IL2R. These results suggest that the genetically engineered ch225-IL2 fusion protein may become a potent immunotherapeutic agent capable of stimulating various immune effector populations to effectively kill human melanoma cells.

AB - Functional characteristics were established for a genetically engineered fusion protein between human IL2 and mouse/human chimeric mAb 225 directed against human epidermal growth factor receptor (EGFR), aberrantly expressed on human melanoma cells. The emphasis of these studies was on the mechanism(s) of action by which the ch225-IL2 fusion protein mediated cytotoxic killing of human melanoma cells by different human immune effector cells. Ch225-IL2 fusion protein bound to human EGFR with the high affinity of the parental antibody, and was as active as the equivalent amount of rhIL2. Ch225-IL2 enhanced cellular cytotoxicity mediated by freshly separated PBMC, isolated natural killer (NK) cells and activated T cells against melanoma cell lines. NK cells, which constitutively express both FcγRIII and IL2R, interacted with ch225-IL2, mainly through FcγRIII, while the involvement of IL2R was secondary. However, the effect of ch225-IL2 on activated T cells was most likely mediated through IL2R. These results suggest that the genetically engineered ch225-IL2 fusion protein may become a potent immunotherapeutic agent capable of stimulating various immune effector populations to effectively kill human melanoma cells.

KW - Cellular cytotoxicity

KW - FcγRIII

KW - IL2R

KW - Immunotherapy

KW - Melanoma

KW - Recombinant antibody-IL2 fusion protein

UR - http://www.scopus.com/inward/record.url?scp=0027772415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027772415&partnerID=8YFLogxK

U2 - 10.1016/0165-2478(93)90169-3

DO - 10.1016/0165-2478(93)90169-3

M3 - Article

C2 - 8144194

AN - SCOPUS:0027772415

VL - 39

SP - 91

EP - 99

JO - Immunology Letters

JF - Immunology Letters

SN - 0165-2478

IS - 1

ER -